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INTRODUCTION
Warfarin therapy is problematic due to a narrow therapeu-
tic index and frequent bleeding complications (1-5). Due to
the significant interpatient variability for warfarin sensitivi-
ty, estimation of the optimal warfarin dose for each patient
is difficult. The prolongation of the prothrombin time (PT)
remains the primary way to measure the anticoagulant effect
of warfarin. Therapy is individualized by monitoring patient’s
international normalized ratio (INR) of PT.
Warfarin metabolism is catalyzed by CYP2C9, which me-
tabolizes S-wafarin to inactive S-7-hydroxywarfarin (4). A
genetic polymorphism of CYP2C9 contributes to the vari-
ability among patients for the required maintenance doses
of warfarin (4). Multiple studies have clearly demonstrated
an increased frequency of CYP2C9 allelic variants such as
CYP2C9*2 and CYP2C9*3 in patients stabilized on low-
dose warfarin therapy. A relationship has been established
between genetic deficiency of the CYP2C9 enzyme activity
and increased likelihood of extremely elevated INRs and
major bleeding events, compared to the general population
(6-11).
In this report, we present a case of warfarin therapy in a
patient with the genotype CYP2C9*3/*4, which resulted
in decreased activity of CYP2C9. Prolonged PT during the
induction phase of standard warfarin therapy was found and
a marked reduction of warfarin dosage was required to get
to the target INR in this case.
CASE REPORT
A 73-yr-old woman with atrial fibrillation presented to
the emergency room complaining of chest discomfort, dys-
pnea, and agitation. The patient had suffered from atrial fib-
rillation for the last 2 yr. Her medications for the previous 2
yr included diltiazem 90 mg, metoprorol 25 mg, and aspirin
100 mg twice a day. In addition, she had been taking mir-
tazapine 30 mg, alprazolam 0.25 mg, and zolpidem 10 mg
daily for a 6 yr history of dysthymia.
Physical examination showed a blood pressure of 100/83
mmHg, a heart rate of 100 beats/min, and a normal body
temperature. Her body weight was 62.3 kg, and she was 158
cm in height. Initial laboratory results were unremarkable
with a normal PT of 12.3 sec (INR 1.0). Routine chemical
studies indicated normal values for total protein (6.6 g/dL),
albumin (3.9 g/dL), aspartate aminotransferase (17 U/L), ala-
nine aminotransferase (10 U/L), alkaline phosphatase (79 U/
L), total bilirubin (0.3 mg/dL) blood urea nitrogen (16.4 mg/
dL), creatinine (0.6 mg/dL), and electrolytes. Results of hema-
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A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with
Extremely Low Warfarin Dose Requirement 
We report a case of intolerance to warfarin dosing due to impaired drug metabolism
in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking
warfarin. She attained a high prothrombin time international normalized ratio (INR)
at the standard doses during the induction of anticoagulation and extremely low
dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Geno-
typing for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This
is the first Korean compound heterozygote for CYP2C9*3 and *4. This case sug-
gests the clinical usefulness of pharmacogenetic testing for individualized dosage
adjustments of warfarin.
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tological studies including complete blood counts were also
normal. Mild cardiomegaly was found on the chest radiog-
raphy. Electrocardiogram showed atrial fibrillation. Echocar-
diogram revealed mild aortic, mitral, and tricuspid regurgi-
tation and left atrial enlargement (45 mm). 
The patient underwent heparinization with an initial bolus
administration of 3,600 IU heparin followed by continuous
infusion for 6 days. Then the patient was started on 2 or 3
mg of warfarin daily (16.3 mg/week) to prevent thromboem-
bolism, and was discharged after 3 days with a PT of 37.4
sec (INR 2.81). When she revisited the outpatient clinic after
3 days, her PT was found to be 50.0 sec (INR 3.68). After
normalization of the patient’s PT with warfarin withdrawal
for 3 days, 1 or 2 mg/day (10.5 mg/week) of warfarin was
prescribed. The PT after 3 days of treatment was 41.6 sec
(INR 3.11). The administration of warfarin dose was changed
(6.5-10.5 mg/week) continuously, which resulted in a PT of
20.9-43.1 sec (INR 1.64-3.21). She had to discontinue war-
farin therapy temporarily 3 times. The difficulty in finding
the optimal treatment dose during the induction period of
anticoagulation continued for more than 2 month.
The patient continues to receive warfarin therapy at the
outpatient clinic monthly and her PT remains within the
recommended target therapeutic range (INR 2.0-3.0), even
though her warfarin dose has been reduced to 6.5 mg/week.
The patient was genotyped for CYP2C9 after informed
consent. DNA was isolated from peripheral blood, and all 9
exons of the CYP2C9 gene were amplified by PCR (11-13).
The PCR products were sequenced using the ABI PRISIM
BigDye terminator Cycle sequencing kit and an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA, U.S.A.). The patient was found to be an intermediate
metabolizer with the genotype of CYP2C9*3/*4(Fig. 1).
DISCUSSION
Genetic polymorphisms of CYP2C9 bring about a signifi-
cant variability among individuals in regard to drug response
(1-4). Patients with genetic variants of CYP2C9 are very sen-
sitive to warfarin, and may become overanticoagulated on a
standard dose. 
More than 20 variant alleles of CYP2C9 have been reported
(14). Previous studies have demonstrated that 2 common
variants CYP2C9*2 and CYP2C9*3 are associated with a
reduced catalytic activity of CYP2C9 (1-11). Therefore, sub-
jects who are homo- or heterozygous for these variant alleles
require reduced maintenance doses for CYP2C9 substrates
such as warfarin. Allele frequencies of CYP2C9 variants have
been shown to be markedly different among populations.
Caucasians possess higher frequencies of CYP2C9*3 than
Asians (6-10% vs. 2-5%) (1-3). There have been no docu-
mented Asian carriers of the CYP2C9*2 variant, while 8-
20% of Caucasians appear to have the CYP2C9*2 allele (1-
11). Yoon et al. reported that from a pool of 574 Koreans
2.3% were heterozygous for CYP2C9*3and none were found
to be carriers of CYP2C9*2 (15). Caucasian and Asian pati-
ents require different warfarin dosages to achieve therapeu-
tic anticoagulation and Asians appear to be more sensitive
to warfarin (2, 9). This can only be partly explained by the
2 most common variant alleles of CYP2C9 in Caucasians,
and there is a possibility that unknown CYP2C9 alleles exist
in Asians. 
This is the first report of a Korean patient with the CYP-
2C9*3/*4 showing warfarin intolerance. The CYP2C9*4
allele including 1076T>C (Ile359Thr) has been reported in
only one Japanese subject (16). However, CYP2C9 variants
other than CYP2C9*2 and CYP2C9*3 have not been stud-
ied in the Korean population. In addition, there has been no
reported Korean subject identified as a compound heterozy-
gote for the 2 variant alleles of CYP2C9. 
The functional significance of the CYP2C9*4allele remains
unclear. However, it is assumed that this allele causes signif-
icant reduction in the CYP2C9 enzyme activity. It is known
that CYP2C9*3, *4, and *5 alleles all lie in a putative sub-
strate recognition site, thus providing an explanation for their
effects on the Km for CYP2C9 substrates (17). The position
of 1076T>C (Ile359Thr) substitution is just close to 1075A
>C (Ile359Leu) in CYP2C9*3, which causes decreased enzyme
activity. Therefore, 1076T>C (Ile359Thr) in CYP2C9*4 is
likely to affect the enzyme activity as 1075A>C (Ile359Leu)
in CYP2C9*3 (16). While the usual maintenance dose of
warfarin is 4-6 mg/day in most patients (28-42 mg/week),
our patient required extremely low doses of warfarin (0.5 or
1 mg/day, 6.5 mg/week) to meet the target INR, suggesting
a poor metabolizer phenotype with 2 functionally deficient
alleles, rather than an intermediate metabolizer phenotype
with 1 deficient allele. Gage et al. reported that homozygotes
for CYP2C9*3 or compound heterozygotes of CYP2C9*3
and CYP2C9*2 had an average daily maintenance warfarin
dose of 1.5 mg and 2.0 mg, respectively, compared to a daily
maintenance dose of 5.1 mg in wildtype (18).
According to the Korean study of Lee et al. (5), 83 patients
visited emergency center for 2 yr due to the bleeding com-
plications or high INR related to warfarin therapy. Lee et al.
reported that one of the main reasons for non-therapeutic
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Fig. 1. Detection of nucleotide changes by sequencing analysis of
CYP2C9 gene in the patient with CYP2C9*3/*4 showing A1075C
(Ile359Leu) and A1076T (Ile359Thr) substitutions (indicated by
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INRs was inadequate dosage adjustment (19) and suggest-
ed a dosing guideline for Korean outpatients with prosthet-
ic heart valves (20). However, the current warfarin dosing
algorithms still do not incorporate genetic factors that could
affect warfarin dose requirements.
Our patient attained a high INR at standard doses and
might be at a higher risk for developing severe complica-
tions. In this patient, we could not identify any specific phar-
macokinetic or pharmacodynamic factors associated with the
warfarin response, such as drug interactions or underlying
disease conditions. Therefore, a pharmacogenetic test was
performed to explore the possible genetic factors contribut-
ing to the unusual warfarin response. This patient could have
taken appropriate therapeutic measures earlier, and be main-
tained on a safer regimen with lower doses, if she had been
genotyped at the beginning of warfarin therapy.
The CYP2C9 genotype is associated with a risk of over-
anticoagulation and bleeding complications. Previous stud-
ies have suggested that a variant group, compared with pa-
tients with the wild-type genotype, require a higher rate of
above-range INR, longer time to reach a therapeutic INR,
smaller maintenance doses, longer time to stable warfarin
dosing, longer hospitalization, and a higher risk of serious
bleeding events (1-4, 6, 7, 11).
CYP2C9 genotyping is recommended to complement PT
monitoring especially when unusual metabolic activity of
warfarin is suspected. Moreover, CYP2C9 genotyping before
the initiation of therapy may serve as an important guide for
more rapid dosage adjustment and prediction of drug response
in each individual in the future. 
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